Enrolled patients have been randomized to one of four weekly treatment arms: VK2735 7.5 mg, 12.5 mg, 17.5 mg, and placebo, a slight amendment from the phase 2 doses, but allowing a higher dose to be examined under a steadier dosing titre than is administered in the phase 2 trial
You may be a candidate if you: Have a BMI of 27 or higher
Please see the Important Safety Information, Full Prescribing Information, and Healthcare Provider Counseling Tool for Patients of Reproductive Potential for Qsymia
Venessa's Formulas, issued a voluntary recall of Ultimate Antioxidant Tablets because they may contain the undeclared allergens crustacean shellfish and milk
Semaglutide addresses metabolic drivers of high cholesterol (excess weight and insulin resistance), while statins directly inhibit cholesterol production in the liver